The main adverse event signals associated with entrectinib used for the treatment of non-small cell lung cancer (NSCLC) are neurological, cardiac and renal disorders, and the importance of structured monitoring for neurologic symptoms, renal function, hemodynamic changes, and cardiac abnormalities, particularly during the early phase is highlighted.
Background Entrectinib is effective for ROS1-positive non-small cell lung cancer (NSCLC), but its postmarketing safety profile remains incompletely characterized outside clinical trials. We conducted a dual-database pharmacovigilance study to characterize real-world reporting patterns, identify cross-database replicate...
Fruquintinib is characterized by a higher proportion of early-onset and potentially unlabeled adverse events, highlighting the need for early and tailored safety monitoring in clinical practice.
Bing Wu, Xin-Ning Yu, Hua-Tao Wu et al.· Journal of Gastrointestinal...· 0 citations
Eribulin is used to treat metastatic breast cancer, but its adverse event (AE) profile requires comprehensive analysis using FDA Adverse Event Reporting System (FAERS) data to guide clinical use. We analyzed eribulin-related AE reports in FAERS (Q1 2011 - Q2 2024). Disproportionality analyses (ROR, PRR, MGPS, BCPNN) id...
Yao Zhou, Jie Gong, Le-Le Shen et al.· PLoS ONE· 0 citations
This large-scale spontaneous-reporting study detected potential safety signals in children using FAERS data from 2017 to 2025, and indicated distinct patterns of adverse‑event reporting across age and sex strata.
Xue-Qing Ma, Jiao-Jiao Fan, Ben Liu· Human Vaccines & Immunothera...· 2 citations
Background Globally, lung cancer is the foremost contributor to cancer-associated fatalities. Of its various histological sub-types, non-small-cell lung cancer (NSCLC) constitutes the vast majority, accounting for more than 85% of diagnoses. A key driver in this pathology is the mesenchymal–epithelial transition (MET)...
Ning Li, Ming-Hua Cong, Jin-Cheng Yang· Drugs in Context· 0 citations
Background Immune checkpoint inhibitors (ICIs) have exhibited remarkable clinical benefits in the treatment of lung cancer, yet a large-scale pharmacovigilance investigation on ICI-related thyroid dysfunction (ICI-TD) remained limited. This study aimed to comprehensively analyze the demographic characteristics of ICI-T...
Ya-Qian Tan, Qi Song· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
